Incyte Corporation - Product Pipeline Review - 2012 - This pharmaceuticals report, "Incyte Corporation - Product Pipeline Review - 2012" provides data on the Incyte Corporation's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from our proprietary databases, Incyte Corporation's corporate website, SEC filings, investor presentations and featured press releases, both from Incyte Corporation and industry-specific third party sources, put together by This team.
Scope
- Incyte Corporation - Brief Incyte Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Incyte Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Incyte Corporation with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Incyte Corporation's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Incyte Corporation's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Incyte Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Incyte Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Incyte Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Incyte Corporation and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of Incyte Corporation; Incyte Corporation - Key Therapeutics; Incyte Corporation - Pipeline Overview and Promising Molecules; Incyte Corporation - News; Incyte Corporation - Latest Updates; Incyte Corporation - Pipeline; Incyte Corporation - Discontinued/Dormant Projects
Table of Contents
Table of Contents
List of Tables
List of Figures
Incyte Corporation Snapshot
Incyte Corporation Overview
Key Information
Key Facts
Incyte Corporation - Research and Development Overview
Key Therapeutic Areas
Incyte Corporation - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Incyte Corporation - Pipeline Products Glance
Incyte Corporation - Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Incyte Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Incyte Corporation - Drug Profiles
INCB024360 + Ipilimumab
Product Description
Mechanism of Action
R&D Progress
INCB242360
Product Description
Mechanism of Action
R&D Progress
Jakafi
Product Description
Mechanism of Action
R&D Progress
Oncology Program
Product Description
Mechanism of Action
R&D Progress
Incyte Corporation - Pipeline Analysis
Incyte Corporation - Pipeline Products by Therapeutic Class
Incyte Corporation - Pipeline Products by Route of Administration
Incyte Corporation - Pipeline Products By Mechanism of Action
Incyte Corporation - Recent Pipeline Updates
Incyte Corporation - Dormant Projects
Incyte Corporation - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
INCB15050
INCB8696
INCB9471
Incyte Corporation - Company Statement
Incyte Corporation - Locations And Subsidiaries
Head Office
Incyte Corporation, Recent Developments
Incyte Corporation- Press Release
Jul 05, 2012: Novartis Receives Health Canada Approval For JAKAVI To Treat Patients With Myelofibrosis
Jun 04, 2012: Incyte Presents New Clinical Data Of Jakafi At ASCO 2012 Annual Meeting
Jun 04, 2012: Incyte Presents Results From Phase I Trial Of INCB024360 At ASCO 2012 Annual Meeting
Apr 20, 2012: CHMP Recommends Novartis's Jakavi To Treat Myelofibrosis Patients
Apr 20, 2012: Incyte Announces EU Regulatory Milestone From Novartis For Ruxolitinib
Feb 29, 2012: Incyte Announces Publication Of Positive Phase III Study Results Of Jakafi In New England Journal Of Medicine
Dec 12, 2009: Incyte Announces Positive Phase I/II Clinical Trial Results Of INCB7839 For The Treatment Of Metastatic Breast Cancer
Dec 07, 2009: Incyte Corporation Announces Three Phase II Trials Results Of INCB18424 At 51st American Society Of Hematology Annual Meeting
Jul 21, 2009: Incyte Reaches Agreement With FDA On A Special Protocol Assessment For INCB18424 In Myelofibrosis
Jun 06, 2009: Results Presented at the ADA 69th Scientific Sessions Demonstrate that INCB13739, Significantly Improves Glycemic Control in Patients with Type 2 Diabetes
May 28, 2009: Incyte Provides Update on Special Protocol Assessment for INCB18424 As A New Treatment for Myelofibrosis
Financial Deals Landscape
Incyte Corporation, Deals Summary
Incyte Corporation, Pharmaceuticals & Healthcare, Deal Details
Licensing Agreements
Incyte Enters Into Licensing Agreement With Eli Lilly
Incyte Enters Into Collaboration And License Agreement With Novartis
Equity Offering
Incyte Completes Public Offering Of $140 Million
Incyte Completes Public Offering Of $109 Million
Debt Offering
Incyte Completes Private Placement Of Convertible Senior Notes Due 2015 For $400 Million
Incyte Completes Private Placement Of $152 Million
Acquisition
Agilent Technologies Acquires Velocity11
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Incyte Corporation, Key Information
Incyte Corporation, Key Facts
Incyte Corporation - Pipeline by Indication, 2012
Incyte Corporation - Pipeline by Stage of Development, 2012
Incyte Corporation - Monotherapy Products in Pipeline, 2012
Incyte Corporation - Combination Treatment Modalities in Pipeline, 2012
Incyte Corporation - Filed, 2012
Incyte Corporation - Phase III, 2012
Incyte Corporation - Phase II, 2012
Incyte Corporation - Phase I, 2012
Incyte Corporation - Pipeline By Therapeutic Class, 2012
Incyte Corporation - Pipeline By Route of Administration, 2012
Incyte Corporation - Pipeline Products By Mechanism of Action, 2012
Incyte Corporation - Recent Pipeline Updates, 2012
Incyte Corporation - Dormant Developmental Projects,2012
Incyte Corporation - Discontinued Pipeline Products, 2012
Incyte Corporation, Deals Summary
Incyte Enters Into Licensing Agreement With Eli Lilly
Incyte Enters Into Collaboration And License Agreement With Novartis
Incyte Completes Public Offering Of $140 Million
Incyte Completes Public Offering Of $109 Million
Incyte Completes Private Placement Of Convertible Senior Notes Due 2015 For $400 Million
Incyte Completes Private Placement Of $152 Million
Agilent Technologies Acquires Velocity11
List of Figures
Incyte Corporation - Pipeline by Indication, 2012
Incyte Corporation - Pipeline by Stage of Development, 2012
Incyte Corporation - Monotherapy Products in Pipeline, 2012
Incyte Corporation - Combination Treatment Modalities in Pipeline, 2012
Incyte Corporation - Pipeline By Route of Administration, 2012
Incyte Corporation - Pipeline Products By Mechanism of Action, 2012 25